| Methods |
Design: three group parallel trial
Purpose: examine the effect of reserpine on schizophrenic patients |
| Participants |
Patients: in‐patients with schizophrenia
Baseline comparability: NS |
| Interventions |
Placebo: NS
Untreated: no reserpine or placebo
Experimental: reserpine
(Co‐intervention: institutionalised patients, beside that NS) |
| Outcomes |
Multidimensional Scale for Rating Psychiatric Patients |
| Notes |
Relevant outcome data not accessible |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Unclear risk |
NS |
| Allocation concealment? |
Unclear risk |
NS |
| Blinding?
Treatment provider |
Low risk |
'Except for the ward psychiatrist and nurse, no personnel involved were aware of patient's treatment. Persons dispensing the placebo were told it was a variant of reserpine' |
| Blinding?
Outcome assessor |
Unclear risk |
NS |
| Incomplete outcome data addressed?
All outcomes |
High risk |
Drop‐out > 15% or NS |
| Free of selective reporting? |
High risk |
Relevant outcome data not accessible |
| Free of other bias? |
Low risk |
|
| Trial size > 49? |
Low risk |
N = 100 |
| Clearly concealed allocation + trial size > 49 + drop‐out max 15% |
High risk |
Drop‐out > 15% or NS |
